Michelle Crank, MD
Allergy & Immunology · Wheaton, MDNPI 1861601650
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 477 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 9.9% — the pattern of someone who eats at a lot of different presentations.
Across 477 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$983
- Octapharma USA, Inc.$930
- Biocryst US Sales Co., LLC$804
- Takeda Pharmaceuticals U.S.A., Inc.$759
- CSL Behring$667
- plus $6K from 30 others
Across 2 payments — averaging $4000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$8K
What the payments were for
- Consulting fees$661%
- Food & beverage$10,70399%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 51 | $1,071 |
| AstraZeneca | 52 | $983 |
| Octapharma USA, Inc. | 18 | $930 |
| Biocryst US Sales Co., LLC | 44 | $804 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $759 |
| CSL Behring | 29 | $667 |
| Pfizer | 38 | $622 |
| Novartis | 23 | $542 |
| Regeneron Healthcare Solutions, Inc. | 22 | $541 |
| Sanofi | 15 | $479 |
| Amgen | 19 | $460 |
| Optinose US, Inc. | 18 | $402 |
| Grifols USA, LLC | 17 | $388 |
| Pharming Healthcare, Inc. | 15 | $359 |
| Genentech USA, Inc. | 13 | $304 |
| Kaleo, Inc. | 11 | $231 |
| Ionis Pharmaceuticals, Inc. | 6 | $139 |
| Aimmune Therapeutics, Inc. | 7 | $131 |
| Teva Pharmaceuticals USA, Inc. | 7 | $123 |
| Blueprint Medicines Corporation | 4 | $114 |
| Alk-abello, Inc | 5 | $98 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $98 |
| Boehringer Ingelheim | 5 | $85 |
| Seqirus USA Inc | 4 | $82 |
| AbbVie | 3 | $76 |
| ADMA Biomanufacturing LLC | 3 | $66 |
| Shire North American Group Inc | 2 | $41 |
| Phadia US Inc. | 2 | $34 |
| Lilly USA, LLC | 2 | $31 |
| Invivyd Inc | 1 | $24 |
| Organon | 1 | $24 |
| Merck | 1 | $23 |
| LEO Pharma Inc. | 1 | $17 |
| GC Biopharma USA, Inc. | 1 | $17 |
| Mylan Pharmaceuticals Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CUTAQUIG$336
How this compares
$10,794 in reported general payments places this provider in the 75th percentile of 105 allergy & immunology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $20,386 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,861 |
| Wixela InhubFluticasone Propion/Salmeterol | 23 | $3,553 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $3,408 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 16 | $3,062 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 50 | $1,234 |
| Azelastine Hcl | 12 | $708 |
| Fluticasone Propionate | 20 | $689 |
| Ipratropium Bromide | 24 | $593 |
| Montelukast Sodium | 30 | $569 |
| Clarithromycin | 11 | $222 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $105 |
| Prednisone | 20 | $105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $1,071 | $20,38616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 105 allergy & immunology providers in Maryland.
Other allergy & immunology in Wheaton
- Mark ScarupaWheaton$508K
- Athena EconomidesWheaton$11K
- Daniel RosloffWheaton$10K
- Martha WhiteWheaton$4K
- Antoine AzarBaltimore$612K
- Sally BaileyBaltimore$344K
- Manav SinglaWhite Marsh$168K
- Sudhir SekhsariaRockville$87K
- Nasim ReedyGaithersburg$63K
- Kristin SokolRockville$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.